Phase 1/2 first-in-human study of U3-1402, an anti-human epidermal growth factor receptor 3 (HER3) antibody-drug conjugate, in HER3-expressing advanced/unresectable or metastatic breast cancer, including those with triple negative breast cancer (TNBC) or HER3-low disease Meeting Abstract
| Authors: | Krop, I.; Masuda, N.; Kogawa, T.; Takahashi, S.; Yonemori, K.; Inoue, K.; Nakayama, T.; Yamamoto, Y.; Alvarez, R.; Toyama, T.; Osaki, A.; Takahashi, M.; O'Shaughnessy, J.; Sagara, Y.; Saji, S.; Kaklamani, V.; Oh, S. Y.; Gradishar, W.; Haley, B.; Iwasa, T.; Traina, T.; Ueno, N.; Isakoff, S.; Ohwada, S.; Tanaka, Y.; Mekan, S.; Onuma, H.; Sharma, O.; Iwata, H. |
| Abstract Title: | Phase 1/2 first-in-human study of U3-1402, an anti-human epidermal growth factor receptor 3 (HER3) antibody-drug conjugate, in HER3-expressing advanced/unresectable or metastatic breast cancer, including those with triple negative breast cancer (TNBC) or HER3-low disease |
| Meeting Title: | 42nd Annual San Antonio Breast Cancer Symposium (SABCS) |
| Journal Title: | Cancer Research |
| Volume: | 80 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2019 Dec 10-14 |
| Meeting Location: | San Antonio, TX |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2020-02-01 |
| Language: | English |
| ACCESSION: | WOS:000527012500095 |
| DOI: | 10.1158/1538-7445.Sabcs19-ot1-07-06 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: OT1-07-06 -- Source: Wos |
